To evaluate the dentoskeletal effects of the Invisalign® Mandibular Advancement (MA) (Align Technology, San José, CA, USA) feature in skeletal Class II growing patients with mandibular retrusion, at pre-pubertal and pubertal stages. MATERIALS AND
Study design: Forty skeletal Class II patients were prospectively recruited and treated with Invisalign® MA. They were divided into two subgroups according to the CVM stage of growth (CVM2 and CVM3) at the beginning of treatment (T0). For each patient, lateral radiographs were collected at the beginning (T0) and at the end of the mandibular advancement treatment (T1) and their measurements were compared with those obtained by an untreated control group of 32 subjects, matched for growth stage and malocclusion.
Patients in CVM2 showed significant reduction of ANB angle, A:Po, Wits index, 11^Spp angle and significant increase of 11^41 and B Downs point. In CVM3 significant reduction of the Wits index and of 41^GoGn angle, and significant increase of the linear Co-Gn measurement, were revealed. Statistics: The STROBE guidelines were followed. Linear regression analysis was performed to estimate the differences of ? (T1 – T0) means between group (control was used as reference) stratifying by CVM levels.
The use of Invisalign® MA is effective in treating Class II growing patient with retrognathic mandible in the short term period. While treatment at prepubertal stage of growth results in dentoalveolar rather than skeletal effects, treatment during the pubertal spurt produces skeletal effects with an annual rate of change of 5.8 mm.
Vol.22 – n.2/2021
Harvard: S. Ravera, T. Castroflorio, F. Galati, G. Cugliari, F. Garino, A. Deregibus, V. Quinzi (2021) "Short term dentoskeletal effects of mandibular advancement clear aligners in Class II growing patients. A prospective controlled study according to STROBE Guidelines", European Journal of Paediatric Dentistry, 22(2), pp119-124. doi: 10.23804/ejpd.2021.22.02.6
Copyright (c) 2021 Ariesdue
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.